BioCryst to Present at the JMP Securities 2017 Life Sciences Conference
June 13 2017 - 6:00AM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that
executives from the Company are scheduled to provide a corporate
summary and update regarding the Company’s clinical programs at the
JMP Securities 2017 Life Sciences Conference in New York on
Wednesday, June 21, 2017 at 9:30 a.m. Eastern Time.
Links to a live audio webcast and replay of the
presentation may be accessed on the BioCryst website events page at
http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and
develops novel small molecule drugs that block key enzymes involved
in rare diseases. BioCryst has several ongoing development
programs: BCX7353 and other second generation oral inhibitors of
plasma kallikrein for hereditary angioedema, and galidesivir, a
broad spectrum viral RNA polymerase inhibitor that is a potential
treatment for filoviruses. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, is
BioCryst's first approved product and has received regulatory
approval in the U.S., Canada, Japan, Taiwan and Korea.
Post-marketing commitment development activities for RAPIVAB are
ongoing, as well as activities to support regulatory approvals in
other territories. For more information, please visit the Company's
website at www.BioCryst.com.
This press release contains forward-looking
statements, including statements regarding future results and
achievements. These statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performances or achievements expressed or implied
by the forward-looking statements. Please refer to the documents
BioCryst files periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024